In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DanioLabs Ltd.

Division of Summit PLC/DanioLabs Ltd.

Latest From DanioLabs Ltd.

INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan

David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.

United Kingdom Strategy

Sosei's Drug Re-Profiling Strategy: A Three-Way Street

By going after Big Pharma's late-stage cast-offs, biotechs that want to be drug developers can lop years off the development time compared to de novo pharmaceutical discovery. The in-licensed compounds have already met, at the least, the druggability hurdle; their intellectual property is nailed down, they've passed the ADMET tests, and they're scalable. This strategy promises to maximize the assets of large company drug originators and give to younger, smaller companies access to compounds for in-licensing. However, the companies that could benefit the most from such an in-licensing strategy, the platform biotechs, often don't. The companies need compounds to move from platforms to product models, but pharma just doesn't see what these partners, based around a single technology and without a presence in the marketplace, can do for them. Now Japan's Sosei Co. Ltd. has come up with a new drug re-profiling strategy that makes licensing a three-way street; for itself, for platform biotechs and for pharmaceutical firms.
BioPharmaceutical North America

In-Licensing: Still a Difficult Model

One way for Pharma to bolster its lagging growth would be to capture some of the value of the compounds it has shelved during development. Start-ups have created technology platforms and systems biology approaches and are in place to reposition such stalled drugs in new indications, or to reformulate marketed compounds to extend the product life cycle. Nonetheless, drug firms largely remain reluctant to part even with compounds they have decided not to develop themselves. Drug makers say the issue is resources, but it is also desire. Until Big Pharma further loosens its grip on its compounds that are stalled in development, in-licensing will remain an opportunistic, case-by-case exercise, and biotechs must accept the fact that access will depend largely on advance insider knowledge of pharma firms' pipelines.
BioPharmaceutical Strategy

Recent Dealmaking (11/2003)

Summarizing the month in European dealmaking.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Summit PLC
  • Senior Management
  • Tony Sedgwick, CEO
    Derek Jones , COO
  • Contact Info
  • DanioLabs Ltd.
    Phone: (44) 1223 706460
    7330 Cambridge Research Park
    Cambridge, CB5 9TN